teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 16 Projects Releases Packages Wiki Activity Actions 66

entity-batch: update 1 entities

Browse source 
- Applied 1 entity operations from queue
- Files: domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md

Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>
This commit is contained in:
Teleo Agents 2026-05-08 17:41:28 +00:00
parent ba6e825324
commit 977621decb
1 changed files with 14 additions and 0 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

14
domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md
View file

@ -13,6 +13,20 @@ sourcer: JMIR / Omada Health
supports: ["healthcares-defensible-layer-is-where-atoms-become-bits-because-physical-to-digital-conversion-generates-the-data-that-powers-ai-care-while-building-patient-trust-that-software-alone-cannot-create"] supports: ["healthcares-defensible-layer-is-where-atoms-become-bits-because-physical-to-digital-conversion-generates-the-data-that-powers-ai-care-while-building-patient-trust-that-software-alone-cannot-create"]
challenges: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics"] challenges: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics"]
related: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "digital-behavioral-support-enables-glp1-dose-reduction-while-maintaining-clinical-outcomes", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp1-long-term-persistence-ceiling-14-percent-year-two", "digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring"] related: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "digital-behavioral-support-enables-glp1-dose-reduction-while-maintaining-clinical-outcomes", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp1-long-term-persistence-ceiling-14-percent-year-two", "digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring"]
### Auto-enrichment (near-duplicate conversion, similarity=1.00)
*Source: PR #10362 — "digital behavioral support improves glp1 persistence 20 percentage points through coaching and monitoring"*
*Auto-converted by substantive fixer. Review: revert if this evidence doesn't belong here.*
related: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "digital-behavioral-support-enables-glp1-dose-reduction-while-maintaining-clinical-outcomes", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp1-long-term-persistence-ceiling-14-percent-year-two", "digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring", "behavioral-glp1-companion-programs-achieve-0-8-percent-weight-maintenance-post-discontinuation-versus-11-12-percent-regain-proving-standalone-behavioral-value"]
## Supporting Evidence
**Source:** Omada Health FY2025 earnings report, March 5, 2026
Omada's Enhanced GLP-1 Care Track achieved 67% persistence at 12 months versus 47-49% comparison cohort (18-20 percentage point improvement). Persistent members achieved 18.4% average weight loss at 12 months; overall cohort 16.3% weight loss, representing 44% better outcomes than semaglutide real-world evidence. This quantifies the behavioral companion program value proposition with specific persistence and outcome data.
--- ---
# Digital behavioral support improves GLP-1 persistence by 20 percentage points (67% vs 47% at 12 months) through integrated coaching and monitoring # Digital behavioral support improves GLP-1 persistence by 20 percentage points (67% vs 47% at 12 months) through integrated coaching and monitoring